Pembrolizumab

Generic Name
Pembrolizumab
Brand Names
Keytruda
Drug Type
Biotech
Chemical Formula
-
CAS Number
1374853-91-4
Unique Ingredient Identifier
DPT0O3T46P
Background

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...

Indication

Pembrolizumab is indicated for the following conditions:

For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.

Associated Conditions
Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Associated Therapies
-
Clinical Trials
Related News

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

First Posted Date
2024-09-23
Last Posted Date
2024-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
750
Registration Number
NCT06607185
Locations
🇨🇳

Hsin-Chu Hospital, Hsin-chu, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

and more 21 locations

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]

First Posted Date
2024-09-23
Last Posted Date
2024-09-23
Lead Sponsor
Aetion, Inc.
Target Recruit Count
851
Registration Number
NCT06607393

Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

First Posted Date
2024-09-20
Last Posted Date
2024-10-28
Lead Sponsor
MedSIR
Target Recruit Count
30
Registration Number
NCT06604858

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting
Conditions
Melanoma
Interventions
Drug: Pembrolizumab
Drug: Nivolumab
First Posted Date
2024-09-19
Last Posted Date
2024-11-06
Lead Sponsor
John Kirkwood
Target Recruit Count
30
Registration Number
NCT06599619
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

First Posted Date
2024-09-19
Last Posted Date
2024-12-09
Lead Sponsor
Alnylam Pharmaceuticals
Target Recruit Count
158
Registration Number
NCT06600321
Locations
🇺🇸

Clinical Trial Site, San Antonio, Texas, United States

🇺🇸

MD Anderson, Houston, Texas, United States

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

First Posted Date
2024-09-19
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
158
Registration Number
NCT06589804
Locations
🇺🇸

Benefis Sletten Cancer Institute, Great Falls, Montana, United States

🇺🇸

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States

🇺🇸

Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States

and more 15 locations

Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs

First Posted Date
2024-09-11
Last Posted Date
2024-09-19
Lead Sponsor
RayzeBio, Inc.
Target Recruit Count
172
Registration Number
NCT06590857
Locations
🇺🇸

Research Facility, Indianapolis, Indiana, United States

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
Aetion, Inc.
Target Recruit Count
304
Registration Number
NCT06585189

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

Phase 1
Not yet recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Trabedersen
Drug: Pembrolizumab
First Posted Date
2024-08-30
Last Posted Date
2024-11-22
Lead Sponsor
University of Nebraska
Target Recruit Count
45
Registration Number
NCT06579196
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

First Posted Date
2024-08-30
Last Posted Date
2024-12-19
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
22
Registration Number
NCT06580054
Locations
🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy